Momenta Pharmaceuticals, Inc. (MNTA) - Financial and Strategic SWOT Analysis Review

Document Sample
Momenta Pharmaceuticals, Inc. (MNTA) - Financial and Strategic SWOT Analysis Review Powered By Docstoc
					         Momenta Pharmaceuticals, Inc. (MNTA) - Financial and Strategic SWOT
                                 Analysis Review
        Reference Code: GDPH57624FSA                                                                                             Publication Date: APR 2013

          675 West Kendall Street                          Phone             +1 617 4919700                         Revenue          283.1 (million USD)
          Cambridge, MA                                    Fax               +1 617 6210431                         Net Profit       -58.65 (million USD)
          02142                                            Website           www.momentapharma.com                  Employees        197
                                                                                                                                     Pharmaceuticals           &
          United States                                    Exchange          MNTA [NASDAQ]                          Industry
                                                                                                                                     Healthcare

       Company Overview
       Momenta Pharmaceuticals, Inc. (Momenta) is a biotechnology company that specializes in the structural analysis of complex
       mixture drugs. The company uses its technology to develop generic versions of complex drug products, as well as to discover
       and develop innovative novel drugs. It also develops generic or biosimilar glycoprotein products to serve the patients better.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Momenta Pharmaceuticals, Inc., SWOT Analysis
         Craig A. Wheeler                    Chief Executive Officer                  Strengths                             Weaknesses
         James R. Sulat                      Chairman
                                                                                      Diversified Product Pipeline          Legal Proceedings
         John K. Clarke                      Director
                                                                                      Strong Technological Base             Lack of Manufacturing Facilities
         Marsha H. Fanucci                   Director
         Peter Barton Hutt                   Director
        Source: Annual Report, Company Website, Primary and Secondary
                                                                                      Opportunities                         Threats
        Research, GlobalData
                                                                                      Alliance and Partnerships             Uncertainties from the Ongoing
       Share Data                                                                                                           R&D Activities
                                                                                      Growing Market for Heparin
         Momenta Pharmaceuticals, Inc.
                                                                                      Drugs                                 Intense Competition
        Share Price (USD) as on 28-Mar-                                13.34
        2013
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        EPS (USD)                                                       -1.16        GlobalData
        Market Cap (million USD)                                         690
        Enterprise Value (million USD)                                   637
        Shares Outstanding (million)                                       52
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Feb 15, 2013         Momenta Pharma             Reports   Revenue        Of
                                                                                                           $12.7m In Q4 2012
                                                                                      Nov 07, 2012         Momenta Pharma Reports Revenue Of $5.1m
                                                                                                           In Q3 2012
                                                                                      Aug 04, 2012         Momenta Acknowledges Federal Circuit
                                                                                                           Opinion Supporting Order Issued January 26,
                                                                                                           2012 In Ongoing Suit Against Amphastar and
                                                                                                           Watson
                                                                                      Aug 02, 2012         Momenta Pharma             Reports   Revenue        Of
       Source: Annual Report, Company Website, Primary and Secondary
                                                                                                           $21.9m In Q2 2012
       Research, GlobalData                                                          Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData




Momenta Pharmaceuticals, Inc. (MNTA) - Financial and Strategic                                                                   Reference Code: GDPH57624FSA
SWOT Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                         Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Momenta Pharmaceuticals, Inc. - Key Facts ...................................................................................................................................... 5
       Momenta Pharmaceuticals, Inc. - Key Employees ............................................................................................................................. 6
       Momenta Pharmaceuticals, Inc. - Key Employee Biographies ........................................................................................................... 7
       Momenta Pharmaceuticals, Inc. - Major Products and Services ........................................................................................................ 8
       Momenta Pharmaceuticals, Inc. - Pharmaceutical Pipeline Products Data ........................................................................................ 9
          Momenta Pharmaceuticals, Inc., Pipeline Products by Therapy Area ............................................................................................ 9
          Momenta Pharmaceuticals, Inc., Pipeline Products by Development Phase ................................................................................ 10
       Momenta Pharmaceuticals, Inc. - History ......................................................................................................................................... 12
       Momenta Pharmaceuticals, Inc. - Company Statement ................................................................................................................... 14
       Momenta Pharmaceuticals, Inc. - Locations And Subsidiaries ......................................................................................................... 17
          Head Office ................................................................................................................................................................................... 17
          Other Locations & Subsidiaries ..................................................................................................................................................... 17
       Section 2 – Company Analysis ......................................................................................................................................................... 18
       Momenta Pharmaceuticals, Inc. - Business Description ................................................................................................................... 18
       Momenta Pharmaceuticals, Inc. - SWOT Analysis ........................................................................................................................... 19
          SWOT Analysis - Overview........................................................................................................................................................... 19
          Momenta Pharmaceuticals, Inc. - Strengths ................................................................................................................................. 19
             Strength - Diversified Product Pipeline ...................................................................................................................................... 19
             Strength - Strong Technological Base ....................................................................................................................................... 19
          Momenta Pharmaceuticals, Inc. - Weaknesses ............................................................................................................................ 19
             Weakness - Legal Proceedings ................................................................................................................................................. 19
             Weakness - Lack of Manufacturing Facilities ............................................................................................................................ 20
          Momenta Pharmaceuticals, Inc. - Opportunities ........................................................................................................................... 20
             Opportunity - Alliance and Partnerships .................................................................................................................................... 20
             Opportunity - Growing Market for Heparin Drugs ...................................................................................................................... 20
             Opportunity - Follow-On Biologics (FOB) Program ................................................................................................................... 20
          Momenta Pharmaceuticals, Inc. - Threats .................................................................................................................................... 21
             Threat - Uncertainties from the Ongoing R&D Activities............................................................................................................ 21
             Threat - Intense Competition ..................................................................................................................................................... 21
             Threat - Government Regulations ............................................................................................................................................. 21
       Momenta Pharmaceuticals, Inc. - Key Competitors .......................................................................................................................... 22
       Section 3 – Company Financial Ratios ............................................................................................................................................. 23
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 23
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 23
       Performance Chart ........................................................................................................................................................................... 25
       Financial Performance...................................................................................................................................................................... 25
       Financial Ratios - Interim Ratios....................................................................................................................................................... 26
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 27
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 28
          Momenta Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 .......................................... 28
          Momenta Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 ......................................... 29


Momenta Pharmaceuticals, Inc. (MNTA) - Financial and Strategic                                                                                                 Reference Code: GDPH57624FSA
SWOT Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Momenta Pharmaceuticals, Inc., Recent Deals Summary................................................................................................................ 30
       Section 5 – Company’s Recent Developments ................................................................................................................................ 31
          Momenta Pharmaceuticals, Inc., Recent Developments............................................................................................................... 31
             Feb 15, 2013: Momenta Pharma Reports Revenue Of $12.7m In Q4 2012.............................................................................. 31
             Nov 07, 2012: Momenta Pharma Reports Revenue Of $5.1m In Q3 2012 ..................................................
				
DOCUMENT INFO
Description: Momenta Pharmaceuticals, Inc. (Momenta) is a biotechnology company that specializes in the structural analysis of complex mixture drugs. The company uses its technology to develop generic versions of complex drug products, as well as to discover and develop innovative novel drugs. It also develops generic or biosimilar glycoprotein products to serve the patients better.
BUY THIS DOCUMENT NOW PRICE: $125 100% MONEY BACK GUARANTEED
PARTNER GlobalData
GlobalData is an industry analysis specialist, providing business information products and services. GlobalData’s highly qualified team of analysts, researchers, and solution consultants use proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries. Sectors and Geographies Covered GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. Research Methodology With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries.